Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study evaluating factors associated to persistence on Golimumab treatment in patients with Inflammatory Arthritis of the Biobadaser Registry

Next Previous
Trial Profile

A study evaluating factors associated to persistence on Golimumab treatment in patients with Inflammatory Arthritis of the Biobadaser Registry

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Jun 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Golimumab (Primary)
  • Indications Axial spondyloarthritis; Psoriatic arthritis; Rheumatoid arthritis
  • Focus Therapeutic Use

    • Most Recent Events

    • 04 Jun 2022 Results presented at the 23rd Annual Congress of the European League Against Rheumatism
    • 04 Jun 2022 Results (n=125) assessing the probability of retention (persistence or drug survival) of golimumab in patients with rheumatic diseases when used after discontinuation of non-TNFi biologicals or tsDMARDs, presented at the 23rd Annual Congress of the European League Against Rheumatism
    • 01 Oct 2021 Updated results assessing the probability of long-term retention of golimumab treatment during up to 7 years after treatment initiation in patients with rheumatoid arthritis (RA), axial spondyloarthritis (SpA), or psoriatic arthritis (PsA), published in the Clinical Rheumatology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top